Amgen Inc. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Amgen Inc. with three other
pharmaceutical manufacturers in North America:
Gilead Sciences, Inc.
(2020
sales of $24.69 billion
of which 100%
was discovery, development and commercializa),
Eli Lilly and Company
($24.54 billion
of which 29%
was Oncology-Verzenio & Other), and
DuPont de Nemours Inc
($20.40 billion
of which 30%
was Nutrition & Biosciences).
Sales Analysis.
Amgen Inc. reported sales of $25.42 billion
for the
year ending
December of 2020.
This
represents
an
increase of 8.8%
versus 2019, when the company's sales were $23.36 billion.
Sales of Other Products saw an increase
that was more than double the company's growth rate: sales were up
32.6% in 2020, from
$4.96 billion to $6.57 billion.
Not all segments of Amgen Inc. experienced an increase in sales in 2020:
sales of Neulasta fell 28.8% to $2.29 billion.
Amgen Inc. also experienced decreases in sales in
Enbrel (down 4.4% to $5.00 billion)
and
Xgeva (down 1.9% to $1.90 billion)
and
Aranesp (down 9.3% to $1.57 billion)
.